Trials for Children with Recurrent DIPG
The following information was gathered by Sue Rooney, mother of Quinn Rooney and JOMD Board member. Sue attempted to contact at least one institution for each open clinical trial to determine both whether a child with DIPG is eligible to participate in the study and to ensure the study is still open. If you find that any of this information is incorrect, please email info@JustOneMoreDay.org so that the list may be corrected. Further, if you are aware of an open trial that is not listed, please email us that information as well.
This list is provided for the sole purpose of helping individuals research. No assessment of the efficacy or advisability of any of the treatments listed has been made or is implied by inclusion in this list. Please note that the order listed was purely random! Please consult your own medical practitioners to determine appropriate medical treatment. Thank you!
1) A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies
Please refer to this study by its ClinicalTrials.gov identifier: NCT00572182
2) ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
3) Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors
ClinicalTrials.gov Identifier: NCT00935545
sharon.gardner@nyumc.org
5) AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Mark Kieran, MD, PhD, Protocol chair Ph: 617-632-4907;Â 866-790-4500
(close to being full per Dr. Kieran)
6) Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
(this will be closing soon per Dr. Blaney (2/15/10))
7) Antineoplaston Therapy in Treating Children With Brain Tumors
info@burzynskiclinic.com
8) Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
(DIPG not technically excluded but may not qualify per Dr. Susan Blaney)
9) Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010) (KTN10010)
Susan Blaney, MD 832-822-4586 smblaney@txccc.edu
10) Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
ClinicalTrials.gov Identifier: NCT00600054
12) Valproate and Etoposide for Patients with Progressive, Relapsed or Refractory Neuronal tumors and Brain Metastases, Phase I clinical trial
Dr. Johannes Wolff 800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
13) Phase I Study Of Single Agent Perifosine For Recurrent Pediatric Solid Tumors
For more information and to inquire about eligibility for this study, please contact
Dr. Oren Becher at 212-639-2152 or Dr. Ira Dunkel at 212-639-2153.
14) Sunitinib in Treating Young Patients With Refractory Solid Tumors
16) Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Jeffrey Bruce, MD jnb2@columbia.edu (reference NCT 00452959)
17) A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors
18) PF-02341066 in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
19) Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Please refer to this study by its ClinicalTrials.gov identifier: NCT01049841
Contact Dr. Oren Becher at 212-639-2152 or Dr. Ira Dunkel at 212-639-2153
20) Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Not Responded to Treatment
(This trial is temporarily closed with an expected date of reopening in mid March 2010)
23) Doxercalciferol in Recurrent Pediatric Solid Tumors
24) Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma
Email: Marites.Francisco@cshs.org
No comments:
Post a Comment